- Home
- WOLF vs ACIU Comparison
WOLF vs ACIU Comparison
Compare WOLF & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WOLF
- ACIU
- Stock Information
- Founded
- WOLF 1987
- ACIU 2003
- Country
- WOLF United States
- ACIU Switzerland
- Employees
- WOLF N/A
- ACIU N/A
- Industry
- WOLF Semiconductors
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- WOLF Technology
- ACIU Health Care
- Exchange
- WOLF Nasdaq
- ACIU Nasdaq
- Market Cap
- WOLF 200.8M
- ACIU 213.3M
- IPO Year
- WOLF 1993
- ACIU 2016
- Fundamental
- Price
- WOLF $2.96
- ACIU $2.48
- Analyst Decision
- WOLF Hold
- ACIU Strong Buy
- Analyst Count
- WOLF 10
- ACIU 2
- Target Price
- WOLF $8.39
- ACIU $10.00
- AVG Volume (30 Days)
- WOLF 28.2M
- ACIU 132.0K
- Earning Date
- WOLF 11-05-2025
- ACIU 11-04-2025
- Dividend Yield
- WOLF N/A
- ACIU N/A
- EPS Growth
- WOLF N/A
- ACIU N/A
- EPS
- WOLF N/A
- ACIU N/A
- Revenue
- WOLF $757,600,000.00
- ACIU $36,362,036.00
- Revenue This Year
- WOLF $16.42
- ACIU N/A
- Revenue Next Year
- WOLF $16.21
- ACIU $1,022.98
- P/E Ratio
- WOLF N/A
- ACIU N/A
- Revenue Growth
- WOLF N/A
- ACIU 86.71
- 52 Week Low
- WOLF $0.39
- ACIU $1.43
- 52 Week High
- WOLF $3.33
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- WOLF 77.79
- ACIU 64.11
- Support Level
- WOLF $1.45
- ACIU $2.12
- Resistance Level
- WOLF $1.98
- ACIU $2.35
- Average True Range (ATR)
- WOLF 0.21
- ACIU 0.13
- MACD
- WOLF 0.16
- ACIU 0.04
- Stochastic Oscillator
- WOLF 89.33
- ACIU 95.74
About WOLF Wolfspeed Inc.
Wolfspeed Inc is involved in the manufacturing of wide bandgap semiconductors. It is focused on silicon carbide and gallium nitride materials and devices for power and radio-frequency (RF) applications. The company serves applications such as transportation, power supplies, inverters, and wireless systems. Geographically, it derives a majority of its revenue from Europe and the rest from the United States, China, Hong Kong, Asia Pacific, and other regions.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.